- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04478266
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (AMEERA-5)
A Randomized, Multicenter, Double-blind Phase 3 Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease
Primary Objective:
To determine whether Amcenestrant (SAR439859) in combination with palbociclib improves progression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease.
Secondary Objective:
- To compare the overall survival in both treatment arms.
- To evaluate the objective response rate in both treatment arms.
- To evaluate the duration of response in both treatment arms.
- To evaluate the clinical benefit rate in both treatment arms.
- To evaluate progression-free survival on next line of therapy.
- To evaluate the pharmacokinetics of amcenestrant, and palbociclib.
- To evaluate health-related quality of life in both treatment arms.
- To evaluate the time to first chemotherapy in both treatment arms.
- To evaluate safety in both treatment arms.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, C1125ABD
- Investigational Site Number :0320004
-
La Rioja, Argentina, 5300
- Investigational Site Number :0320003
-
Mar del Plata, Argentina, B7600FYK
- Investigational Site Number :0320009
-
Salta, Argentina, 4400
- Investigational Site Number :0320007
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentina, C1012AAR
- Investigational Site Number :0320001
-
Caba, Buenos Aires, Argentina, C1019ABS
- Investigational Site Number :0320005
-
Capital Federal, Buenos Aires, Argentina, C1417DTB
- Investigational Site Number :0320008
-
Pergamino, Buenos Aires, Argentina, B2700CPM
- Investigational Site Number :0320006
-
-
Córdoba
-
Cordoba, Córdoba, Argentina, 5000
- Investigational Site Number :0320010
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, 2000
- Investigational Site Number :0320002
-
-
-
-
New South Wales
-
Macquarie Park, New South Wales, Australia, 2109
- Investigational Site Number :0360004
-
Randwick, New South Wales, Australia, 2031
- Investigational Site Number :0360005
-
Wahroonga, New South Wales, Australia, 2076
- Investigational Site Number :0360003
-
-
Victoria
-
Richmond, Victoria, Australia, 3121
- Investigational Site Number :0360002
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Investigational Site Number :0360001
-
-
-
-
-
Graz, Austria, 8036
- Investigational Site Number :0400001
-
-
-
-
-
Bruxelles, Belgium, BE-1200
- Investigational Site Number :0560003
-
Charleroi, Belgium, B-6000
- Investigational Site Number :0560004
-
Leuven, Belgium, 3000
- Investigational Site Number :0560001
-
Namur, Belgium, 5000
- Investigational Site Number :0560002
-
-
-
-
-
Rio De Janeiro, Brazil, 20230-130
- Investigational Site Number :0760004
-
São Paulo, Brazil, 04321-120
- Investigational Site Number :0760008
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035 003
- Investigational Site Number :0760005
-
Porto Alegre, Rio Grande Do Sul, Brazil, 91350-250
- Investigational Site Number :0760006
-
-
São Paulo
-
Sao Paulo, São Paulo, Brazil, 01509-900
- Investigational Site Number :0760007
-
Sao Paulo, São Paulo, Brazil, 04014-002
- Investigational Site Number :0760003
-
-
-
-
-
Burgas, Bulgaria, 8000
- Investigational Site Number :1000004
-
Dobrich, Bulgaria
- Investigational Site Number :1000005
-
Russe, Bulgaria, 7002
- Investigational Site Number :1000008
-
Sofia, Bulgaria, 1797
- Investigational Site Number :1000001
-
-
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Investigational Site Number :1240004
-
Toronto, Ontario, Canada, M4N 3M5
- Investigational Site Number :1240002
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Investigational Site Number :1240007
-
Montreal, Quebec, Canada, H3T 1S6
- Investigational Site Number :1240014
-
Montreal, Quebec, Canada, H4A 3J1
- Investigational Site Number :1240005
-
-
-
-
-
Santiago, Chile, 7500921
- Investigational Site Number :1520007
-
Santiago de Chile, Chile
- Investigational Site Number :1520003
-
-
Coquimbo
-
La Serena, Coquimbo, Chile, 1720430
- Investigational Site Number :1520005
-
-
La Araucanía
-
Temuco, La Araucanía, Chile, 4810561
- Investigational Site Number :1520004
-
-
Maule
-
Talca, Maule, Chile
- Investigational Site Number :1520009
-
-
Reg Metropolitana De Santiago
-
Santaigo, Reg Metropolitana De Santiago, Chile, 8241470
- Investigational Site Number :1520011
-
Santiago, Reg Metropolitana De Santiago, Chile, 7650568
- Investigational Site Number :1520006
-
Santiago, Reg Metropolitana De Santiago, Chile, 8420383
- Investigational Site Number :1520002
-
-
Valparaíso
-
Viña del Mar, Valparaíso, Chile, 2520598
- Investigational Site Number :1520001
-
-
-
-
-
Baoding, China, 071000
- Investigational Site Number :1560038
-
Beijing, China, 100142
- Investigational Site Number :1560008
-
Beijing, China, 100730
- Investigational Site Number :1560035
-
Changchun, China, 130021
- Investigational Site Number :1560003
-
Changchun, China, 130041
- Investigational Site Number :1560036
-
Chengdu, China, 610041
- Investigational Site Number :1560013
-
Chongqing, China, 400030
- Investigational Site Number :1560019
-
Dalian, China, 116011
- Investigational Site Number :1560031
-
Dalian, China, 116027
- Investigational Site Number :1560021
-
Deyang, China, 618000
- Investigational Site Number :1560054
-
Fuzhou, China, 354200
- Investigational Site Number :1560043
-
Guangzhou, China, 510080
- Investigational Site Number :1560025
-
Hangzhou, China, 310003
- Investigational Site Number :1560006
-
Hangzhou, China, 310009
- Investigational Site Number :1560007
-
Hangzhou, China, 310016
- Investigational Site Number :1560002
-
Hangzhou, China, 310022
- Investigational Site Number :1560005
-
Harbin, China, 150081
- Investigational Site Number :1560011
-
Hefei, China, 233004
- Investigational Site Number :1560041
-
Jinan, China, 250013
- Investigational Site Number :1560018
-
Jinan, China, 250117
- Investigational Site Number :1560046
-
Jining, China
- Investigational Site Number :1560051
-
Linyi, China, 276000
- Investigational Site Number :1560017
-
Luoyang, China, 471003
- Investigational Site Number :1560055
-
Neijiang, China, 641003
- Investigational Site Number :1560048
-
Shanghai, China, 200032
- Investigational Site Number :1560001
-
Shaoguan, China, 512025
- Investigational Site Number :1560037
-
Tianjin, China, 300060
- Investigational Site Number :1560028
-
Wuhan, China, 430060
- Investigational Site Number :1560033
-
Wuhan, China, 430079
- Investigational Site Number :1560024
-
Xi'An, China, 710061
- Investigational Site Number :1560044
-
Xi'an, China, 710004
- Investigational Site Number :1560045
-
Xuzhou, China, 221009
- Investigational Site Number :1560027
-
Yantai, China, 264000
- Investigational Site Number :1560049
-
Zhengzhou, China, 450008
- Investigational Site Number :1560022
-
-
-
-
-
Brno, Czechia, 65653
- Investigational Site Number :2030001
-
Praha 2, Czechia, 12808
- Investigational Site Number :2030002
-
-
-
-
-
Helsinki, Finland, 00029
- Investigational Site Number :2460001
-
Tampere, Finland, 33520
- Investigational Site Number :2460002
-
Turku, Finland, FIN-20520
- Investigational Site Number :2460003
-
-
-
-
-
Nice, France, 06189
- Investigational Site Number :2500009
-
Paris, France, 75010
- Investigational Site Number :2500003
-
Paris, France, 75248
- Investigational Site Number :2500001
-
Poitiers, France, 86021
- Investigational Site Number :2500006
-
Saint Cloud, France, 92210
- Investigational Site Number :2500007
-
Saint-Herblain, France, 44805
- Investigational Site Number :2500002
-
Strasbourg, France, 67033
- Investigational Site Number :2500010
-
TOULOUSE Cedex 9, France, 31059
- Investigational Site Number :2500005
-
Villejuif, France, 94800
- Investigational Site Number :2500004
-
-
-
-
-
Batumi, Georgia, 6000
- Investigational Site Number :2680005
-
Kutaisi, Georgia, 4600
- Investigational Site Number :2680006
-
Tbilisi, Georgia, 0112
- Investigational Site Number :2680001
-
Tbilisi, Georgia, 0144
- Investigational Site Number :2680002
-
Tbilisi, Georgia, 0159
- Investigational Site Number :2680004
-
Tbilisi, Georgia, 0159
- Investigational Site Number :2680007
-
Tbilisi, Georgia, 0168
- Investigational Site Number :2680003
-
-
-
-
-
Bottrop, Germany, 46236
- Investigational Site Number :2760006
-
Münster, Germany, 48149
- Investigational Site Number :2760003
-
Oldenburg in Holstein, Germany, 23758
- Investigational Site Number :2760007
-
Ulm, Germany, 89075
- Investigational Site Number :2760001
-
-
-
-
-
Budapest, Hungary, 1115
- Investigational Site Number :3480008
-
Gyula, Hungary, 5700
- Investigational Site Number :3480011
-
Győr, Hungary, 9023
- Investigational Site Number :3480005
-
Kaposvár, Hungary, 7400
- Investigational Site Number :3480003
-
Kecskemét, Hungary, 6000
- Investigational Site Number :3480009
-
Miskolc, Hungary, 3526
- Investigational Site Number :3480010
-
Nyíregyháza, Hungary, 4400
- Investigational Site Number :3480001
-
-
-
-
-
Bologna, Italy, 40138
- Investigational Site Number :3800010
-
Milano, Italy, 20141
- Investigational Site Number :3800002
-
Milano, Italy, 20132
- Investigational Site Number :3800004
-
Napoli, Italy, 80131
- Investigational Site Number :3800006
-
Prato, Italy, 59100
- Investigational Site Number :3800005
-
-
Emilia-Romagna
-
Meldola (FC), Emilia-Romagna, Italy, 47014
- Investigational Site Number :3800008
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- Investigational Site Number :3800003
-
-
Monza E Brianza
-
Monza, Monza E Brianza, Italy, 20052
- Investigational Site Number :3800007
-
-
-
-
Aichi
-
Nagoya-shi, Aichi, Japan, 460-0001
- Investigational Site Number :3920016
-
Nagoya-shi, Aichi, Japan, 464-8681
- Investigational Site Number :3920007
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- Investigational Site Number :3920002
-
-
Ehime
-
Matsuyama-shi, Ehime, Japan, 791-0280
- Investigational Site Number :3920009
-
-
Fukuoka
-
Kurume-shi, Fukuoka, Japan, 830-0013
- Investigational Site Number :3920019
-
-
Gunma
-
Takasaki-shi, Gunma, Japan, 370-0829
- Investigational Site Number :3920017
-
-
Hiroshima
-
Hiroshima-shi, Hiroshima, Japan, 730-8518
- Investigational Site Number :3920010
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 003-0804
- Investigational Site Number :3920001
-
-
Kagoshima
-
Kagoshima-shi, Kagoshima, Japan, 892-0833
- Investigational Site Number :3920012
-
-
Kanagawa
-
Yokohama-shi, Kanagawa, Japan, 241-8515
- Investigational Site Number :3920006
-
Yokohama-shi, Kanagawa, Japan, 222-0036
- Investigational Site Number :3920014
-
-
Miyagi
-
Sendai-shi, Miyagi, Japan, 980-0803
- Investigational Site Number :3920020
-
-
Miyazaki
-
Miyazaki-shi, Miyazaki, Japan, 880-8510
- Investigational Site Number :3920022
-
-
Osaka
-
Osaka-shi, Osaka, Japan, 540-0006
- Investigational Site Number :3920008
-
Osaka-shi, Osaka, Japan, 553-0003
- Investigational Site Number :3920018
-
-
Saitama
-
Hidaka-shi, Saitama, Japan, 350-1241
- Investigational Site Number :3920013
-
-
Shizuoka
-
Shizuoka-shi, Shizuoka, Japan, 420-8527
- Investigational Site Number :3920021
-
-
Tokyo
-
Koto-ku, Tokyo, Japan, 135-8550
- Investigational Site Number :3920003
-
Meguro-ku, Tokyo, Japan, 152-8902
- Investigational Site Number :3920015
-
Shinagawa-ku, Tokyo, Japan, 142-8666
- Investigational Site Number :3920005
-
-
-
-
-
Seochogu, Korea, Republic of, 6591
- Investigational Site Number :4100009
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13496
- Investigational Site Number :4100008
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 10408
- Investigational Site Number :4100006
-
Seongnam, Gyeonggi-do, Korea, Republic of, 463-707
- Investigational Site Number :4100005
-
-
Seoul-teukbyeolsi
-
Seoul, Seoul-teukbyeolsi, Korea, Republic of, 02841
- Investigational Site Number :4100007
-
Seoul, Seoul-teukbyeolsi, Korea, Republic of, 03722
- Investigational Site Number :4100004
-
Seoul, Seoul-teukbyeolsi, Korea, Republic of, 110-744
- Investigational Site Number :4100003
-
Seoul, Seoul-teukbyeolsi, Korea, Republic of, 135-710
- Investigational Site Number :4100002
-
Seoul, Seoul-teukbyeolsi, Korea, Republic of, 138-878
- Investigational Site Number :4100001
-
-
-
-
-
Arnhem, Netherlands, 6815 AD
- Investigational Site Number :5280006
-
Delft, Netherlands, 2625 AD
- Investigational Site Number :5280005
-
Maastricht, Netherlands, 6229 HX
- Investigational Site Number :5280001
-
-
-
-
Lódzkie
-
Tomaszow Mazowiecki, Lódzkie, Poland, 97-200
- Investigational Site Number :6160002
-
-
Wielkopolskie
-
Poznan, Wielkopolskie, Poland, 61-866
- Investigational Site Number :6160007
-
-
-
-
-
Almada, Portugal, 2801-951
- Investigational Site Number :6200005
-
Lisboa, Portugal, 1649-035
- Investigational Site Number :6200001
-
Porto, Portugal, 4200-319
- Investigational Site Number :6200002
-
-
-
-
-
Arkhangelsk, Russian Federation, 163045
- Investigational Site Number :6430007
-
Krasnogorskiy District, Russian Federation, 143423
- Investigational Site Number :6430004
-
Moscow, Russian Federation, 115478
- Investigational Site Number :6430008
-
Moscow, Russian Federation, 117186
- Investigational Site Number :6430003
-
Moscow, Russian Federation, 117997
- Investigational Site Number :6430005
-
Moscow, Russian Federation, 129090
- Investigational Site Number :6430006
-
Moscow Region, Russian Federation, 143442
- Investigational Site Number :6430009
-
Saint -Petersburg, Russian Federation, 197758
- Investigational Site Number :6430001
-
Saint Petersburg, Russian Federation, 199034
- Investigational Site Number :6430010
-
-
-
-
-
Singapore, Singapore, 119228
- Investigational Site Number :7020002
-
Singapore, Singapore, 169610
- Investigational Site Number :7020004
-
Singapore, Singapore, 329563
- Investigational Site Number :7020001
-
-
-
-
-
Cape Town, South Africa, 7570
- Investigational Site Number :7100004
-
Johannesburg, South Africa, 1709
- Investigational Site Number :7100006
-
-
-
-
-
Madrid, Spain, 28041
- Investigational Site Number :7240001
-
Málaga, Spain, 29010
- Investigational Site Number :7240007
-
Valencia, Spain, 46015
- Investigational Site Number :7240009
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], Spain, 08017
- Investigational Site Number :7240011
-
-
Castilla Y León
-
Barcelona / Sabadell, Castilla Y León, Spain, 08208
- Investigational Site Number :7240008
-
-
Galicia [Galicia]
-
Santiago de Compostela, Galicia [Galicia], Spain, 15706
- Investigational Site Number :7240003
-
-
Madrid, Comunidad De
-
Madrid, Madrid, Comunidad De, Spain, 28046
- Investigational Site Number :7240004
-
Madrid / Madrid, Madrid, Comunidad De, Spain, 28007
- Investigational Site Number :7240006
-
Madrid / Madrid, Madrid, Comunidad De, Spain, 28050
- Investigational Site Number :7240002
-
-
Valenciana, Comunidad
-
Valencia, Valenciana, Comunidad, Spain, 46010
- Investigational Site Number :7240005
-
-
-
-
-
Kaohsiung, Taiwan, 807
- Investigational Site Number :1580007
-
Tainan, Taiwan
- Investigational Site Number :1580002
-
Taipei, Taiwan, 100
- Investigational Site Number :1580001
-
Taipei, Taiwan, 10449
- Investigational Site Number :1580003
-
-
-
-
-
Adana, Turkey, 01120
- Investigational Site Number :7920006
-
Ankara, Turkey, 06100
- Investigational Site Number :7920008
-
Ankara, Turkey, 06200
- Investigational Site Number :7920009
-
Antalya, Turkey, 07070
- Investigational Site Number :7920007
-
Bornova, Turkey, 35100
- Investigational Site Number :7920005
-
Diyarbakır, Turkey, 21100
- Investigational Site Number :7920013
-
Edirne, Turkey, 22030
- Investigational Site Number :7920003
-
Istanbul, Turkey, 34214
- Investigational Site Number :7920001
-
Istanbul, Turkey, 34457
- Investigational Site Number :7920011
-
Istanbul, Turkey, 34722
- Investigational Site Number :7920004
-
Kocaeli, Turkey, 41380
- Investigational Site Number :7920010
-
Malatya, Turkey, 44280
- Investigational Site Number :7920002
-
İzmir, Turkey, 0000
- Investigational Site Number :7920012
-
-
-
-
-
Kharkiv, Ukraine, 61103
- Investigational Site Number :8040004
-
Kharkiv, Ukraine, 61166
- Investigational Site Number :8040010
-
Kryvyi Rih, Ukraine, 50048
- Investigational Site Number :8040001
-
Odesa, Ukraine, 65025
- Investigational Site Number :8040002
-
Vinnytsia, Ukraine, 21029
- Investigational Site Number :8040007
-
-
-
-
Central Bedfordshire
-
Glasgow, Central Bedfordshire, United Kingdom, G12 0YN
- Investigational Site Number :8260001
-
-
Edinburgh, City Of
-
Edinburgh, Edinburgh, City Of, United Kingdom, EH4 2XU
- Investigational Site Number :8260002
-
-
Lancashire
-
Blackburn, Lancashire, United Kingdom, BB2 3HH
- Investigational Site Number :8260005
-
-
-
-
Alabama
-
Daphne, Alabama, United States, 36526
- Investigational Site Number :8400075
-
-
Arizona
-
Glendale, Arizona, United States, 85308
- Investigational Site Number :8400083
-
Tucson, Arizona, United States, 85712
- Investigational Site Number :8400066
-
-
California
-
Fullerton, California, United States, 92835
- Investigational Site Number :8400038
-
Los Alamitos, California, United States, 90720
- Investigational Site Number :8400056
-
Santa Monica, California, United States, 90404
- Investigational Site Number :8400029
-
-
Colorado
-
Denver, Colorado, United States, 80262
- Investigational Site Number :8400025
-
-
Florida
-
Lakeland, Florida, United States, 33805
- Investigational Site Number :8400059
-
Orlando, Florida, United States, 32804
- Investigational Site Number :8400053
-
Palm Bay, Florida, United States, 32901
- Investigational Site Number :8400081
-
-
Georgia
-
Athens, Georgia, United States, 30607
- Investigational Site Number :8400055
-
Atlanta, Georgia, United States, 30342
- Investigational Site Number :8400016
-
Savannah, Georgia, United States, 31405
- Investigational Site Number :8400034
-
Thomasville, Georgia, United States, 31792
- Investigational Site Number :8400035
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Investigational Site Number :8400039
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46804
- Investigational Site Number :8400008
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Investigational Site Number :8400006
-
-
Kansas
-
Westwood, Kansas, United States, 66205-2003
- Investigational Site Number :8400013
-
-
Maine
-
Scarborough, Maine, United States, 04074-9308
- Investigational Site Number :8400028
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Investigational Site Number :8400017
-
Danvers, Massachusetts, United States, 01923
- Investigational Site Number :8400076
-
Newton, Massachusetts, United States, 02463
- Investigational Site Number :8400077
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Investigational Site Number :8400002
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Investigational Site Number :8400005
-
Saint Louis, Missouri, United States, 63141
- Investigational Site Number :8400004
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
- Investigational Site Number :8400058
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901-1914
- Investigational Site Number :8400015
-
Paramus, New Jersey, United States, 00000
- Investigational Site Number :8400024
-
-
New York
-
New York, New York, United States, 10016
- Investigational Site Number :8400010
-
Stony Brook, New York, United States, 11794-8121
- Investigational Site Number :8400023
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Investigational Site Number :8400009
-
-
Oregon
-
Tigard, Oregon, United States, 97223
- Investigational Site Number :8400067
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- Investigational Site Number :8400001
-
-
Texas
-
Austin, Texas, United States, 78745
- Investigational Site Number :8400073
-
Dallas, Texas, United States, 75231
- Investigational Site Number :8400072
-
Dallas, Texas, United States, 75246
- Investigational Site Number :8400070
-
Denton, Texas, United States, 76021
- Investigational Site Number :8400080
-
Houston, Texas, United States, 77024
- Investigational Site Number :8400061
-
Houston, Texas, United States, 77024
- Investigational Site Number :8400068
-
Plano, Texas, United States, 75093
- Investigational Site Number :8400084
-
The Woodlands, Texas, United States, 77380
- Investigational Site Number :8400086
-
Waco, Texas, United States, 76712
- Investigational Site Number :8400078
-
Webster, Texas, United States, 77598
- Investigational Site Number :8400082
-
-
Virginia
-
Blacksburg, Virginia, United States, 24060
- Investigational Site Number :8400085
-
Winchester, Virginia, United States, 22601
- Investigational Site Number :8400069
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria :
- Adult participants with loco-regional recurrent or metastatic disease not amenable to curative treatment.
- Confirmed diagnosis of ER+/HER2- breast cancer.
- No prior systemic treatment for loco-regional recurrent or metastatic disease.
- Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors (RECIST) v.1.1 or non-measurable bone-only disease.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Participants should be willing to provide tumor tissue.
- Capable of giving informed consent.
Exclusion criteria:
- Known active brain metastases.
- Prior neo (adjuvant) treatment with any selective estrogen receptor degrader (SERD).
- Inadequate organ and marrow function.
- Disease recurrence while on, or within 12 months of completion of (neo)adjuvant endocrine therapy.
- Pregnant, breastfeeding, or woman of childbearing potential unwilling to use recommended contraception methods.
- Male participants who disagree to follow contraception.
- Participants with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term.
- Participants with significant concomitant illness.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Letrozole + Palbociclib
Participants received letrozole 2.5 milligrams (mg) capsule along with amcenestrant-matching placebo once daily, continuously and palbociclib 125 mg orally (PO), once daily (QD) from Day 1 to Day 21 of each 28-day treatment cycle until disease progression, death or study cut-off date, whichever comes first (maximum exposure: 112 weeks).
Goserelin once every 4 weeks in pre/peri menopausal women and men.
|
Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
Other Names:
Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
Pharmaceutical form: Tablets Route of Administration: Oral
Pharmaceutical form: Capsules Route of Administration: Orally
|
Experimental: Amcenestrant + Palbociclib
Participants received amcenestrant 200 mg tablet along with letrozole-matching placebo once daily, continuously and palbociclib 125 mg PO, QD from Day 1 to Day 21 of each 28-day treatment cycle until disease progression, death, or study cut-off date, whichever comes first (maximum exposure: 109 weeks).
Goserelin once every 4 weeks in pre/peri menopausal women and men.
|
Pharmaceutical form: Tablets Route of Administration: Oral
Other Names:
Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
Other Names:
Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
Pharmaceutical form: Capsules Route of Administration: Orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS)
Time Frame: From randomization to the date of first documented tumor progression or death due to any cause or data cut-off date whichever comes first (maximum duration: 81 weeks)
|
PFS was defined as the time interval (in months) from the date of randomization to the date of first documented tumor progression as per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) assessed by local radiologist or investigator, or death (due to any cause), whichever comes first.
Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions.
Analysis was performed by Kaplan-Meier method.
|
From randomization to the date of first documented tumor progression or death due to any cause or data cut-off date whichever comes first (maximum duration: 81 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12-month Progression-free Survival (PFS) Rate
Time Frame: Month 12
|
Percentage of participants who were disease progression-free at Month 12 after randomization were reported in this outcome measure.
PFS was defined as the time interval (in months) from the date of randomization to the date of first documented tumor progression as per RECIST 1.1 assessed by local radiologist or investigator, or death (due to any cause), whichever comes first.
PD as per RECIST 1.1: at least a 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions.
The PFS rate at Month 12 was estimated using the Kaplan-Meier method and provided an estimation of the percentage of participants who were disease progression-free at Month 12 after randomization.
|
Month 12
|
Pharmacokinetics: Plasma Concentrations of Amcenestrant
Time Frame: Cycle 1 Day 1: 3 hours (hr) post-dose, Cycle 1 Day 15: pre-dose, Cycle 2 Day 1: pre-dose, 3 hr post-dose, Cycle 2 Day 15: pre-dose, Cycle 3 Day 1: pre-dose, Cycle 4 Day 1: pre-dose, Cycle 7 Day 1: pre-dose, Cycle 10 Day 1: pre-dose
|
Amcenestrant plasma concentrations at specified time points were reported.
Data for this outcome measure was not planned to be collected and analyzed for Letrozole+Palbociclib arm as pre-specified in protocol.
|
Cycle 1 Day 1: 3 hours (hr) post-dose, Cycle 1 Day 15: pre-dose, Cycle 2 Day 1: pre-dose, 3 hr post-dose, Cycle 2 Day 15: pre-dose, Cycle 3 Day 1: pre-dose, Cycle 4 Day 1: pre-dose, Cycle 7 Day 1: pre-dose, Cycle 10 Day 1: pre-dose
|
Pharmacokinetics: Plasma Concentrations of Palbociclib
Time Frame: Cycle 1 Day 1: 3 hr post-dose, Cycle 1 Day 15: pre-dose, Cycle 2 Day 1: pre-dose, 3 hr post-dose, Cycle 2 Day 15: pre-dose, Cycle 3 Day 1: pre-dose, Cycle 4 Day 1: pre-dose, Cycle 7 Day 1: pre-dose, Cycle 10 Day 1: pre-dose
|
Palbociclib plasma concentrations at specified time points were reported.
|
Cycle 1 Day 1: 3 hr post-dose, Cycle 1 Day 15: pre-dose, Cycle 2 Day 1: pre-dose, 3 hr post-dose, Cycle 2 Day 15: pre-dose, Cycle 3 Day 1: pre-dose, Cycle 4 Day 1: pre-dose, Cycle 7 Day 1: pre-dose, Cycle 10 Day 1: pre-dose
|
Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30) Domain Scores
Time Frame: Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
|
EORTC-QLQ-C30: cancer-specific instrument with 30 questions for evaluation of new chemotherapy & assessment of participant reported outcome.
These include 5 functional scales, 9 symptom scales, & Global Health Status/quality of life scale (GHS/QoL).
All 14 items/domains were scored on scale of 1 (not at all) to 4 (very much) & GHS/QoL, scored on scale of 1 (very poor) to 7 (excellent).
All scales are transformed from raw scores to linear scales ranging 0 to 100.
Higher score for functional & GHS/QoL=higher level of functioning, & higher score for symptoms scales=higher symptom burden.
Least Square (LS) mean and Standard Error (SE) were derived from MMRM model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect.
Average of LS mean change from Baseline values of overall treatment (i.e., each cycle [Cycle 1 up to Cycle 21]) for each domain was reported in this outcome measure.
|
Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
|
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Breast Cancer Specific Module (EORTC-QLQ-BR23) Domain Scores
Time Frame: Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
|
QLQ-BR23: disease-specific Health-related QOL assesses breast cancer impact & side effects of treatment.
EORTCQLQ- BR23 contains 23 items: multi-item scales & single-item measures.
4 functional scales (body image, sexual functioning, sexual enjoyment, future perspective) & 4 scales related to symptoms of disease or treatment (arm symptoms, breast symptoms, systemic therapy side effects, & upset by hair loss).
All items scored 1 (not at all) to 4 (very much).
Scores of all scales transformed from raw scores to linear scales ranging 0-100.
Higher score for functional scales=better outcome; higher score for symptoms scales=higher symptom burden.
LS mean & SE were derived from MMRM model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value & stratifications factors as fixed effect.
Average of LS mean change from Baseline values of overall treatment (i.e., each cycle [Cycle 1 up to Cycle 21]) for each domain was reported.
|
Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
|
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Breast Cancer Specific Module (EORTC QLQ-BR45) Domain Scores
Time Frame: Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
|
EORTC QLQ-BR45: comprised of all 23 items from the QLQ-BR23 plus an additional 22 items assessing endocrine therapy symptoms (10 items), endocrine sexual symptoms (4 items), breast satisfaction (2 items), and skin mucosis symptoms (6 items).
All items scored 1 (not at all) to 4 (very much).
Scores of all scales transformed from raw scores to linear scales ranging 0 to 100.
Higher score for functional scales = better outcome; higher score for symptoms scales = higher symptom burden.
LS mean and SE are derived from Mixed Model Repeated Measures (MMRM) model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect.
Average of LS mean change from Baseline values of overall treatment (i.e., each cycle [Cycle 1 up to Cycle 21]) for each domain (endocrine therapy symptoms, endocrine sexual symptoms, breast satisfaction and skin mucosis symptoms) was reported.
|
Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
|
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Visual Analog Scale (VAS) Score
Time Frame: Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
|
EQ-5D-5L is a standardized measure of health status, provides a simple, generic measure of health for clinical and economic appraisal, and consists of 2 sections: the EQ-5D-5L health state utility index (descriptive system) and the EQ-5D-5L VAS.
The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
LS mean and SE are derived from MMRM model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect.
Average of LS mean change from Baseline values of overall treatment (i.e., each cycle [Cycle 1 up to Cycle 21]) for VAS was reported in this outcome measure.
|
Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
|
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Health Utility Index Value Score
Time Frame: Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
|
EQ-5D-5L: consists of 2 sections: EQ-5D-5L health state utility index (descriptive system) & VAS.
The EQ-5D descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort & anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, & extreme problems.
Response options are measured with 5-point Likert scale (for 5L version).
The EQ-5D-5L responses are converted into single index utility score between 0 to 1, where higher score indicates better health state & lower score indicate worse health state.
LS mean and SE were derived from MMRM model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect.
Average of LS mean change from Baseline values overall treatment (i.e., each cycle [Cycle 1 up to Cycle 21]) for health utility index value score was reported in this outcome measure.
|
Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
|
Overall Survival (OS)
Time Frame: From randomization to the death due to any cause or data cut-off date, whichever comes first (maximum duration: 81 weeks)
|
OS was defined as the interval (in months) from the date of randomization to the date of documented death (due to any cause).
In the absence of observation of death, survival time was censored to last date the participant was known to be alive or at the cut-off date, whichever comes first.
Analysis was performed by Kaplan-Meier method.
|
From randomization to the death due to any cause or data cut-off date, whichever comes first (maximum duration: 81 weeks)
|
Percentage of Participants With Objective Response
Time Frame: From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (maximum duration: 81 weeks)
|
Objective response was defined as percentage of participants having a partial response (PR) or complete response (CR) according to the RECIST version 1.1 assessed by investigator.
As per RECIST 1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeters (mm).
PR was defined as at least a 30%decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters.
|
From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (maximum duration: 81 weeks)
|
Duration of Response (DOR)
Time Frame: From the date of first response of CR or PR until disease progression or death, or start of any anti-cancer therapy or data cut-off date, whichever comes first (maximum duration: 81 weeks)
|
DOR was defined as time (in months) from first documented evidence of CR or PR until disease progression determined by investigator as per RECIST 1.1, or start of any anti-cancer therapy, or death from any cause, whichever occurs first.
For participants with ongoing response at the time of the analysis, DOR was censored at the date of the last valid disease assessment not showing documented progression performed before the initiation of a new anticancer treatment (if any).
As per RECIST 1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters.
PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions.
Analysis was performed by Kaplan-Meier method.
|
From the date of first response of CR or PR until disease progression or death, or start of any anti-cancer therapy or data cut-off date, whichever comes first (maximum duration: 81 weeks)
|
Percentage of Participants With Clinical Benefit
Time Frame: From randomization until disease progression, or death, or data cut-off date, whichever comes first (maximum duration: 81 weeks)
|
Clinical Benefit was defined as the percentage of participants having a confirmed CR, PR, or stable disease (SD) for at least 24 weeks determined by investigator as per RECIST 1.1, from date of randomization until disease progression, or death, or data cut-off date, or initiation of post treatment anti-cancer therapy, whichever occurs first.
As per RECIST 1.1; CR was defined as disappearance of all target, non-target lesions & normalization of tumor marker level.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference Baseline sum diameters.
SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum diameters.
PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions.
|
From randomization until disease progression, or death, or data cut-off date, whichever comes first (maximum duration: 81 weeks)
|
Progression-free Survival on Next Line of Therapy (PFS2)
Time Frame: From randomization to date first documented disease progression on the next systemic anti-cancer therapy, or death due to any cause, or data cut-off date, whichever comes first (maximum duration: 81 weeks)
|
PFS2 was defined as the time interval (in months) from the date of randomization to the date of first documentation of PD on the next systemic anti-cancer therapy according to investigator, or death due to any cause in the absence of documented PD on the next systemic anti-cancer therapy, whichever occurs first.
PD was defined as at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions.
Analysis was performed by Kaplan-Meier method.
|
From randomization to date first documented disease progression on the next systemic anti-cancer therapy, or death due to any cause, or data cut-off date, whichever comes first (maximum duration: 81 weeks)
|
Time to First Chemotherapy
Time Frame: From randomization to the start date of the first chemotherapy (maximum duration: 81 weeks)
|
Time to chemotherapy was defined as the time interval (in months) from the date of randomization to the start date of the first chemotherapy after disease progression.
|
From randomization to the start date of the first chemotherapy (maximum duration: 81 weeks)
|
Number of Participants With Hematological Abnormalities During the Treatment Period
Time Frame: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 112 weeks)
|
Hematological parameters assessed were anemia, lymphocyte count decreased, neutrophil count decreased, white blood cell decreased, platelet count decreased.
Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 5.0 (NCI-CTCAE v 5.0), where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening.
Grade refers to the severity of the AEs.
Treatment period was defined as the time from the first dose of study treatments up to 30 days after last dose of study treatment.
|
From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 112 weeks)
|
Number of Participants With Liver Function Abnormalities of Grade 3 and 4 During the Treatment Period
Time Frame: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 112 weeks)
|
Liver Function parameters assessed were aspartate aminotransferase increased, alanine aminotransferase increased, alkaline phosphatase increased, total bilirubin increased, gamma-glutamyl transferase increased.
Parameters were assessed as per the NCI-CTCAE v 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening.
Grade refers to the severity of the AEs.
Treatment period was defined as the time from the first dose of study treatments up to 30 days after last dose of study treatment.
Participants with Grade 3 and 4 liver function abnormalities were reported in this outcome measure.
|
From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 112 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Sciences & Operations, Sanofi
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
- Palbociclib
- Goserelin
Other Study ID Numbers
- EFC15935
- 2020-001824-33 (EudraCT Number)
- U1111-1233-0486 (Other Identifier: UTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on SAR439859
-
SanofiCompletedBreast Cancer | Healthy VolunteersUnited Kingdom
-
SanofiActive, not recruiting
-
SanofiTerminatedBreast CancerFrance, Belgium, United States, Italy, Japan, Puerto Rico, Russian Federation, Spain, Ukraine
-
SanofiActive, not recruitingBreast CancerCzechia, Belgium, Spain, United States, France, Canada, Italy, Poland, Portugal, United Kingdom
-
QuantumLeap Healthcare CollaborativeRecruitingBreast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast CancerUnited States